NCT00738335撤回1 期
A Phase I Open-Label, Dose-Finding Study to Evaluate the Safety and Efficacy of Concurrent Radiosurgery and Erlotinib Administration in Non-Small Cell Lung Cancer Patients With Brain Metastases
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Acute and long-term toxicity (i.e., neurotoxicity, gastrointestinal, cutaneous, and hematologic) as assessed by NCI CTCAE v3.0.
研究概览
简要总结
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Stereotactic radiosurgery may be able to deliver x-rays directly to the tumor and cause less damage to normal tissue. Erlotinib may make tumor cells more sensitive to radiation therapy. Giving erlotinib together with stereotactic radiosurgery may kill more tumor cells.
PURPOSE: This phase I clinical trial is studying the side effects of erlotinib when given together with stereotactic radiosurgery and to see how well it works in treating patients with non-small cell lung cancer with brain metastases.
详细描述
OBJECTIVES:
Primary
- To determine the acute as well as long-term toxicity (especially grade III neurotoxicity) of concurrent erlotinib hydrochloride and single-fraction radiosurgery in patients with non-small cell lung cancer (NSCLC) and brain metastases.
Secondary
- To determine the freedom from progression in all detected lesions (i.e., radiosurgically treated and untreated) and the rate of response of radiosurgically treated lesions in patients receiving concurrent erlotinib hydrochloride and radiosurgery as compared with historical controls treated with gamma knife radiosurgery alone at UCSF.
- To measure the rate of freedom from any CNS progression in these patients at 1 year post treatment.
- To assess cerebrospinal fluid (CSF) distribution of erlotinib hydrochloride by measuring both erlotinib hydrochloride and its major metabolite, OSI-420, in plasma and CSF at 4 or more days after initial erlotinib hydrochloride administration but before radiosurgery, and again at 4 weeks after stereotactic radiosurgery (optional).
- To perform CSF and serum biomarker analysis for NSCLC using 2-dimensional liquid chromatography or mass spectrometry (2D-LC/MS).
- To determine the incidence of subclinical leptomeningeal disease in patients assigned to gamma-knife treatment and who do not exhibit signs or symptoms or carcinomatous meningitis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed non-small cell lung cancer (NSCLC) meeting the following criteria:
- •Fewer than 5 intraparenchymal brain metastases by gadolinium-enhanced MRI meeting the following criteria:
- •Maximum diameter ≤ 4.0 cm
- •If multiple lesions are present and one lesion is > 3.0 cm, the remaining lesions must be ≤ 3.0 cm in maximum diameter
- •No metastases within 3 mm of the optic nerve or optic chiasm such that some portion of the optic nerve or chiasm would receive > 9 Gy from radiosurgery
- •No metastases in the brainstem, midbrain, pons, or medulla
- •No prior complete resection of a single brain metastasis or of all known brain metastases
- •Subtotal resection allowed provided residual disease is ≤ 4.0 cm in maximum diameter
- •No clinical or radiographic evidence of unstable systemic progression (other than the study lesion[s]) within the past month
- •Patients with brain metastases at initial presentation do not require 1 month of scans documenting stable disease
- •Isolated brain metastases with stable systemic disease allowed
- •No leptomeningeal metastases by MRI and/or positive cerebrospinal fluid cytology
- •PATIENT CHARACTERISTICS:
- •Karnofsky performance status 60-100%
- •Life expectancy ≥ 3 months
- •ANC > 1,000/mm³
- •Platelet count > 100,000/mm³
- •Hemoglobin > 10 g/dL
- •PT and PTT normal
- •AST < 2 times upper limit of normal (ULN)
- •Alkaline phosphatase < 2 times ULN
- •Total bilirubin < 2 times ULN
- •Lactic dehydrogenase < 2 times ULN
- •Serum creatinine < 1.5 times ULN
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception during and for ≥ 2 weeks after completion of study therapy
- •Neurologic function status 0-2
- •No history of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib hydrochloride
- •No contraindication to MRI (e.g., cardiac pacemaker)
- •No absolute contraindication to lumbar puncture
- •PRIOR CONCURRENT THERAPY:
- •See Disease Characteristics
- •Prior systemic therapy allowed
- •No prior cranial radiotherapy
- •Prior radiotherapy to noncranial sites allowed
- •More than 1 week since prior intrathecal chemotherapy or prior treatment of leptomeningeal carcinoma
- •No concurrent systemic therapy
- •Prior or current erlotinib hydrochloride for treatment of systemic disease allowed provided systemic disease has not progressed while on erlotinib hydrochloride
- •No concurrent enzyme-inducing anticonvulsant
- •If patients are on an enzyme-inducing anticonvulsant (e.g., phenytoin, carbamazepine, or phenobarbital), the agent must be converted to a nonenzyme-inducing anticonvulsant before or at the start of erlotinib hydrochloride treatment
- •No concurrent CYP3A4 inhibitors or inducers (e.g., Hypericum perforatum [St. John wort] or ketoconazole)
- •No other concurrent investigational therapy
排除标准
- 未提供
结局指标
主要结局
Acute and long-term toxicity (i.e., neurotoxicity, gastrointestinal, cutaneous, and hematologic) as assessed by NCI CTCAE v3.0.
次要结局
- Disease progression
- Response rate of radiosurgically treated lesions in patients receiving concurrent erlotinib hydrochloride and radiosurgery on this study vs the response rate of historical controls previously treated with gamma knife radiosurgery alone
- CNS progression at 1 year
- Distribution of erlotinib hydrochloride in plasma and cerebrospinal fluid (CSF)
- CSF and serum biomarkers
- Incidence of subclinical leptomeningeal disease
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerLung CancerNCT00100854Translational Oncology Research International108
已完成
1 期
A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal CancerStage IIIC Rectal CancerMucinous Adenocarcinoma of the RectumSignet Ring Adenocarcinoma of the ColonMucinous Adenocarcinoma of the ColonStage IIIA Colon CancerStage IIIA Rectal CancerRecurrent Rectal CancerSignet Ring Adenocarcinoma of the RectumStage IIIB Rectal CancerStage IVB Colon CancerRecurrent Colon CancerStage IVA Rectal CancerStage IVB Rectal CancerStage IIIB Colon CancerStage IIIC Colon CancerStage IVA Colon CancerNCT00060411National Cancer Institute (NCI)24
终止
1 期
Erlotinib in Treating Patients With Progressive Glioblastoma MultiformeBrain and Central Nervous System TumorsNCT00227032UNC Lineberger Comprehensive Cancer Center10
终止
2 期
Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by SurgeryStage IB Pancreatic CancerStage III Pancreatic CancerStage IA Pancreatic CancerIntraductal Papillary Mucinous Neoplasm of the PancreasRecurrent Pancreatic CancerStage IIA Pancreatic CancerStage IIB Pancreatic CancerNCT00482625National Cancer Institute (NCI)6
终止
不适用
Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast CancerBreast CancerNCT00503841Barbara Ann Karmanos Cancer Institute44